Viatris (VTRS) vs peers
VTRS's P/E is not meaningful or is unavailable. Choose another measure to compare peers.
Pharmaceuticals. Updated .
| Stock | P/E | Own 5-year rank |
|---|---|---|
| VTRSViatris | Unavailable | Unranked |
| MRKMerck & Co. | 119.0x | 90% |
| LLYLilly (Eli) | 42.6x | 18% |
| PFEPfizer | 39.3x | 95% |
| BMYBristol Myers Squibb | 13.5x | 13% |
| ZTSZoetis | 13.1x | 8% |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
P/E divides the share price by earnings per share from the previous twelve months. The middle peer reading excludes VTRS and unavailable values.
Own 5-year rank compares each stock with its available weekly readings within the last five years. At least 26 usable weeks are required. A rank of 20% means its current multiple is above 20% of its past readings. It is not a rank against the other stocks in this table.
Dates show data updates; the latest available weekly observation can differ between stocks. Different growth rates, margins and financial risks can explain different multiples. Missing or non-positive denominators are left unranked.